Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials - SUPPLEMENTARY MATERIALS

Name: Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials - SUPPLEMENTARY MATERIALS
Creator: Andrew Blauvelt
Published: 2024-02-12T15:17:19.482Z
Keywords: Depression, Clinical Trial, Mental Health, Biologicals, Suicide, Psoriasis

Blauvelt, Andrew; Armstrong, April; Merola, Joseph; Strober, Bruce; de Cuyper, Dirk; Peterson, Luke; Davies, Owen; Stark, Jeffrey; Lebwohl, Mark

doi:10.17632/tk5wky7t5s.2

Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials - SUPPLEMENTARY MATERIALS

Published: 12 February 2024| Version 2 | DOI: 10.17632/tk5wky7t5s.2

Contributors:

Andrew Blauvelt, April Armstrong, Joseph Merola, Bruce Strober, Dirk de Cuyper, Luke Peterson, Owen Davies, Jeffrey Stark, Mark Lebwohl

Description

Supplementary Materials for the manuscript titled 'Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials'.

Files

Funding

UCB Pharma (United Kingdom)

Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials - SUPPLEMENTARY MATERIALS

Description

Files

Categories

Funding

Licence